Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442130 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00442130 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants.
The verdict
NCT00442130, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the safety and immune activity of a vaccine made from the participant's own cancer cells, when administered after a reduced intensity transplant. In recent years, researchers at Dana-Farber Cancer Institute have discovered that vaccines made from a patients's own cancer cells, that have been engineered in the laboratory to produce a protein called GM-CSF, can be effective in stimulating a powerful immune response specific to that cancer.
Interventions
- PROCEDURE stem cell transplantation
- BIOLOGICAL GM-K562 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-02 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442130
The ClinicalTrials.gov registry entry for NCT00442130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which stem cell transplantation is the first listed.
NCT00442130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442130 about?
NCT00442130 is a clinical study titled "Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination". The purpose of this research study is to assess the safety and immune activity of a vaccine made from the participant's own cancer cells, when administered after a reduced intensity transplant. In recent years, researchers at Dana-Farber Cancer Institute have discovered that vaccines made from a pat...
What is the current status of trial NCT00442130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-02. Estimated completion is 2020-04.
What interventions are being tested in trial NCT00442130?
The interventions under investigation include: stem cell transplantation (PROCEDURE), GM-K562 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00442130?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.